Printer Friendly

DURA PHARMACEUTICALS REPORTS CONTINUED RECORD SALES FOR SECOND QUARTER AND FIRST SIX MONTHS OF 1993

 SAN DIEGO, July 20 /PRNewswire/ -- Dura Pharmaceuticals Inc. (NASDAQ: DURA), a national developer and marketer of pharmaceutical products for the treatment of allergies and asthma, today announced record sales for the seventh consecutive quarter.
 For the second quarter ended June 30, 1993, sales grew 77 percent to $4,008,000 from $2,265,400 in the same period of 1992, with gross profit margins continuing to run in excess of 70 percent. Pharmaceutical sales rose 98 percent compared to the same period last year, while device sales decreased 4 percent. Dura announced recently that it has signed a letter of intent to sell the assets of its device division to Pari Respiratory Equipment Inc.
 As expected, expenses related to Dura's rapid sales force expansion contributed to a net loss for the quarter of $1,819,000, or $.24 per share, as compared to a net loss of $1,221,700, or $.16 per share, in the second quarter of 1992. Since the second quarter of 1992, Dura's sales force has grown 75 percent from 72 to 126 at the end of the second quarter of 1993. Also impacting second quarter 1993 results by approximately $.06 per share was the company's stepped-up investment in the development of its dry powder inhaler (DPI), a novel dry powder drug delivery system. Dura is currently pursuing various corporate partnering arrangements to fund the future development of the DPI which could mitigate or eliminate the impact of DPI development expenses on Dura's future operating results.
 For the six months ended June 30, 1993, Dura reported a loss of $3,798,700, or $.51 per share, on increased sales of $7,605,000, compared to a net loss of $2,266,900, or $.31 per share, on sales of $4,243,000 in the same period of 1992.
 Historically, Dura's sales have grown more rapidly during the first and fourth quarters than during the second and third quarters as a result of the winter cold and flu season. Quarter-to-quarter sales growth of 11 percent for the second quarter of 1993 was less than growth of 19 percent in the first quarter of 1993 and 31 percent in the fourth quarter of 1992 because of the seasonal nature of Dura's business.
 Dura President and Chief Executive Officer Cam Garner, commenting on the results said, "We are progressing nicely as we build toward profitability through the growth in our sales force and the development of our proprietary respiratory products. We've made significant progress on the advancement of our DPI technology, including the signing of a substantial new technology development agreement with SRI International and the acceleration of our licensing efforts with major pharmaceutical companies."
 Dura Pharmaceuticals Inc. is a San Diego-based developer and marketer of prescription pharmaceutical products, drug delivery systems and medical devices for the treatment of allergies, asthma and related respiratory conditions.
 DURA PHARMACEUTICALS INC.
 Second Quarter Results
 Three Months Ended Six Months Ended
 June 30, June 30,
 1993 1992 1993 1992
 Statement of Operations
 Sales $4,008,000 $2,265,400 $7,605,000 $4,243,000
 Cost & expenses
 Cost of sales 1,063,000 567,600 2,020,100 1,222,700
 Clinical, devel. & reg. 644,200 360,300 996,600 606,500
 Gen. admin. & mktg. 4,032,400 2,649,400 8,091,500 4,698,700
 Goodwill & other 87,400 (90,200) 295,500 (18,000)
 Net loss ($1,819,000)($1,221,700)($3,798,700)($2,266,900)
 Net loss per share (24 cents) (16 cents) (51 cents) (31 cents)
 Weighted average
 common shares 7,494,561 7,460,402 7,492,179 7,199,505
 June 30, 1993 June 30, 1992
 Summary Balance Sheet Data
 Cash and marketable securities $7,376,200 $17,839,500
 Other current assets 3,091,400 2,244,700
 Other assets 11,485,700 5,858,400
 Total $21,953,300 $25,942,600
 Current liabilities $2,551,200 $1,710,100
 Long-term obligations 4,734,100 1,580,700
 Shareholders' equity 14,668,000 22,651,800
 Total $21,953,300 $25,942,600
 -0- 7/20/93
 /CONTACT: James W. Newman, VP-Finance and Administration of Dura Pharmaceuticals, 619-457-2553/
 (DURA)


CO: Dura Pharmaceuticals Inc. ST: California IN: MTC SU: ERN

MF-JL -- SD003 -- 6580 07/20/93 08:46 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1993
Words:716
Previous Article:BELL ATLANTIC REPORTS STRONG SECOND-QUARTER 1993 EARNINGS
Next Article:HORIZON BANK REPORTS HIGHER FIRST QUARTER EARNINGS AND NEW OFFICE LOCATIONS
Topics:


Related Articles
DURA PHARMACEUTICALS REPORTS FIRST QUARTER 1993 OPERATING RESULTS; SALES UP 82 PERCENT
DURA PHARMACEUTICALS REPORTS OPERATING RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF 1993
DURA PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 1993 RESULTS
DURA PHARMACEUTICALS ACHIEVES FIRST PROFITABLE QUARTER ON RECORD SALES
DURA PHARMACEUTICALS REPORTS CONTINUED PROFITABILITY FOR THIRD QUARTER 1994
DURA PHARMACEUTICALS REPORTS FIRST FULL YEAR OF PROFITABILITY FOR YEAR ENDED DEC. 31, 1994
DURA PHARMACEUTICALS REPORTS CONTINUED PROFITABILITY, RECORD REVENUES AND EARNINGS FOR THE QUARTER ENDED MARCH 31, 1995
DURA PHARMACEUTICALS REPORTS CONTINUED PROFITABILITY, RECORD REVENUES AND EARNINGS FOR THE QUARTER ENDED JUNE 30, 1995
Dura Pharmaceuticals, Inc. Announces Results For The Second Quarter of 1999.
Dura Pharmaceuticals Announces a 24% Increase In Year-Over-Year Earnings for the Second Quarter of 2000.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters